Oral anticoagulant therapy in Italian patients 80 yr of age or older with atrial fibrillation: A pilot study of low vs. standard PT/INR targets

European Journal of Haematology

Volumn 89, Issue 1, 2012, Pages 81-86

  Cafolla, Arturo ^a   Campanelli, Melissa ^a   Baldacci, Erminia ^a   Potasso, Laura ^a   Bochicchio, Raffaele ^a   Dragoni, Francesco ^a   Foà, Roberto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Low PT INR target; Oral anticoagulant therapy; Patients over 80 yr of age

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; ITALY; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTHROMBIN TIME; STROKE; THROMBOSIS;

EID: 85027945953     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01786.x     Document Type: Article

References (26)

1. Indik JH, Alpert JS. The patient with atrial fibrillation. Am J Med 2009;122:415-8.
2. Wolf PA, Benjamin E, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: the Framingham Heart Study. Am Heart J 1996;131:790-5.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
4. Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin: fourth edition. Br J Haematol 2011;154:311-24.
5. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: american College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:1095-100.
6. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
7. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004;164:880-4.
8. Torn M, Bollen WL, van der Meer FJ, van der Waal EE, Rosendaal FR. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005;165:1527-32.
9. Poli D, Antonucci E, Grifonio E, Abbate R, Gensini GF, Prisco D. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol 2009;54:999-1002.
10. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
11. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. Should patients characteristics influence target anticoagulation target intensity for stroke prevention in non valvular atrial fibrillation? The ATRIA study Circ Cardiovasc Qual Outcomes 2009;2:297-304.
12. You JH, Chan FW, Wong RS, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clinical Pharm 2005;59:582-7.
13. Pengo V, Cucchini U, Denas G, Davidson BL, Marzot F, Jose SP, Iliceto S. Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly Warfarin-experienced patients with non-valvular atrial fibrillation. Thromb Haemost 2010;103:442-9.
14. Fuster V, Ryden LE, Cannom DS, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; Writing Committee to Revise the 2001 Guidelines for the management of Patients with Atrial Fibrillation. J Am Coll Cardiol 2006;48:854-906.
15. Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007;109:2419-23.
16. Cafolla A, Melizzi R, Baldacci E, Pignoloni P, Dragoni F, Campanelli M, Caraccini R, Foà R. 'Zeus' a new oral anticoagulant therapy dosing algorithm: a cohort study. Thrombosis Res 2011;128:325-30.
17. Poller L, Keown M, Ibrahim S, et al. An International multicenter randomized study of computer-assisted oral anticoagulant dosage vs medical staff dosage. J Thromb Haemost 2008;6:935-43.
18. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briet E. A method to determine the optimal intensity of an oral anticoagulant therapy. Thromb Haemost 1993;69:236-9.
19. Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general Medicare population: a 10-year perspective (1992 to 2002). Stroke 2006;37:1969-74.
20. Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011;40:675-83.
21. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Inter Med 2001;40:1183-8.
22. Hylek EM, Skates SJ, Sheehan MA, Singer D. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.
23. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer D. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26.
24. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
25. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long- term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-72.
26. Legrand M, Mateo J, Aribaud A, et al. The use of Dabigatran in elderly patients. Arch Intern Med 2011;171:1285-8.